Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice

被引：3
作者：
Lally, Lindsay [1 ]
Spiera, Robert [1 ]
机构：
[1] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2018年 / 32卷 / 06期
关键词：
Polymyalgia rheumatica; Giant cell arteritis; Corticosteroids; Biologics; Large-vessel vasculitis; PLACEBO-CONTROLLED TRIAL; POPULATION-BASED COHORT; DOUBLE-BLIND; FOLLOW-UP; RHEUMATISM/AMERICAN COLLEGE; EMISSION-TOMOGRAPHY; EUROPEAN LEAGUE; METHOTREXATE; TOCILIZUMAB; RELAPSE/RECURRENCE;
D O I：
10.1016/j.berh.2019.04.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role of various large-vessel imaging modalities to help confirm a diagnosis of GCA. Systemic corticosteroids (CS) remain the mainstay of treatment for both PMR and GCA, yet both relapses and CS-related side effects are common. Recent research has demonstrated efficacy of certain biologic agents in these diseases, with particular emphasis on the role of interleukin-6 (IL-6) blockade in GCA. This chapter discusses the latest updates on the diagnosis and treatment of PMR/GCA, with an emphasis on clinical care. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码：803 / 812
页数：10
相关论文
共 42 条
[1]   Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database [J].
Albrecht, Katinka ;
Huscher, Doerte ;
Buttgereit, Frank ;
Aringer, Martin ;
Hoese, Guido ;
Ochs, Wolfgang ;
Thiele, Katja ;
Zink, Angela .
RHEUMATOLOGY INTERNATIONAL, 2018, 38 (04) :569-577
[2]   Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis [J].
Bley, T. A. ;
Reinhard, M. ;
Hauenstein, C. ;
Markl, M. ;
Warnatz, K. ;
Hetzel, A. ;
Uhl, M. ;
Vaith, P. ;
Langer, M. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (08) :2574-2578
[3]   Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients [J].
Blockmans, D. ;
De Ceuninck, L. ;
Vanderschueren, S. ;
Knockaert, D. ;
Mortelmans, L. ;
Bobbaers, H. .
RHEUMATOLOGY, 2007, 46 (04) :672-677
[4]   Polymyalgia Rheumatica and Giant Cell Arteritis A Systematic Review [J].
Buttgereit, Frank ;
Dejaco, Christian ;
Matteson, Eric L. ;
Dasgupta, Bhaskar .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (22) :2442-2458
[5]   Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study [J].
Cantini, F ;
Salvarani, C ;
Olivieri, I ;
Macchioni, L ;
Ranzi, A ;
Niccoli, L ;
Padula, A ;
Boiardi, L .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2000, 30 (01) :17-24
[6]   Prednisone plus methotrexate for polymyalgia rheumatica - A randomized, double-blind, placebo-controlled trial [J].
Caporali, R ;
Cimmino, MA ;
Ferraccioli, G ;
Gerli, R ;
Klersy, C ;
Salvarani, C ;
Montecucco, C .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (07) :493-500
[7]  
Chevalet P, 2000, J RHEUMATOL, V27, P1484
[8]  
Cimmino MA, 2008, CLIN EXP RHEUMATOL, V26, P395
[9]   Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial [J].
Conway, Richard ;
O'Neill, Lorraine ;
Gallagher, Phil ;
McCarthy, Geraldine M. ;
Murphy, Conor C. ;
Veale, Douglas J. ;
Fearon, Ursula ;
Molloy, Eamonn S. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) :523-528
[10]   Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015 [J].
Crowson, Cynthia S. ;
Matteson, Eric L. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) :253-256
12345